Cobalis Corp.

Cobalis Corp., a development stage company, engages in the development and commercialization of pharmaceutical products for allergic diseases. Its product includes PreHistin, a phase III clinical trial product candidate for the treatment of atopic allergic diseases, including seasonal and year-round allergies, migraine, dermatitis, food allergies, and asthma. The company was incorporated in 2000 and is based in Irvine, California. On November 19, 2007, the involuntary petition of Cobalis Corp. for liquidation under Chapter 7 bankruptcy was converted to voluntary Chapter 11 reorganization. The involuntary petition was filed on August 1, 2007.